| Methods |
Design:
randomized,placebo‐ controlled, double‐blind
parallel groups
9 months |
| Participants |
Country: U.S.A.
n=20 DAT (DSM?), mild dementia (CDRS <2)
Aged 77 (SD 6, 67‐86). Exclusion criteria: Depression (GDS >5), age < 70, Other types of dementia syndromes |
| Interventions |
1. CEE oral 0.625 mg/day + MPA 5 mg for 15 days every 3rd mth
2. Placebo |
| Outcomes |
General (BIMC)
Memory (CERAD word list, Paired Associates, Digit Span), Speed (TMT), Other (Clock drawing) |
| Notes |
HRT >placebo: on Paired associate, Placebo > HRT: on BMIC, Digit Span 1/6 tests |
